Subject Expert Committee of union government on April 12 approved Dr Reddy's application for emergency use authorisation to Russian COVID vaccine 'Sputnik V' in India. With this, India has now three COVID-19 vaccines in use. Welcoming the step, Medical Superintendent of RML Hospital, Dr Rana AK Singh...
Russia on May 06 approved Sputnik Light, the single-dose vaccine against COVID-19. According to the information on Sputnik V's twitter handle, the single-dose vaccine has 79.4% overall efficacy against coronavirus, and is a "reliable pandemic fighter". Sputnik V, which is approved in 64 countries with a total population of over 3.2 billion people, has already started arriving in India for emergency use.
From DCGI approving new anti-Covid drug, to health ministry issues new rules for hospital admissions, here are the top updates on the coronavirus. DCGI approved a new anti-Covid oral drug, which has been developed by DRDO and Dr. Reddy’s. The medicine has been given emergency use approval by DCGI. Meanwhile, Health Ministry said that a positive Covid-19 report is now not mandatory for a patient to be admitted to a hospital. Also, Supreme Court formed a 12-member National Task Force on medical oxygen. The new panel includes 10 doctors and 2 top bureaucrats from the Centre, who will ensure streamlined delivery of oxygen across India. Watch the full video for more updates on the pandemic.
Credit: HT Digital Content Duration: 03:24Published
Drugs Controller General of India (DCGI) on May 08 approved emergency use DRDO's anti-COVID drug which the agency said will be helpful in faster recovery of hospitalised patients. While speaking to ANI, Institute of Nuclear Medicine and Allied Sciences (INMAS-DRDO) scientists spoken about drug 2-deoxy-D-glucose (2-DG). The drug will be of immense benefit to the people suffering from COVID-19.
The Drugs Controller General of India has granted permission for emergency use of therapeutic application of drug 2-deoxy-D-glucose or 2-DG as adjunct therapy. This was used to treat cancer and showed efficacy in Covid treatment.
#Covid #2DG #EmergencyUse
Institute of Nuclear Medicine and Allied Sciences-DRDO scientist Dr Sudhir Chandna on drug 2-deoxy-D-glucose (2-DG) while speaking to ANI informed about the observations of the medicine's clinical trials. "110 patients in ph 2 and 220 patients in ph 3 participated in clinical trials. It has shown better efficacy in ph 2. Recovery was 2-3 days faster for COVID patients. Phase 3 data shows by day 3, freedom from oxygen dependence seen in 42% patients as compared to 31% patients who were in standard care," said Dr Sudhir Chandna. Further referring to the data obtained he said that oxygen dependence reduced in a better way when we use this medicine along with standard care. "The pricing will depend on the production and those factors are with Dr. Reddy's Laboratories who are our industry partners," said DRDO scientist. On medicine's roll out, he said that it might come out in few days.
Sputnik V is a minus 18-degrees Celsius storage vaccine, informed Ravi Mathur, Global Logistics' Head, Dr Reddy's Laboratories after the Russian vaccines arrived in India on May 01."Sputnik V is a minus 18-degrees Celsius storage vaccine. We have created a state-of-the-art central warehouse that operates below minus 20-degrees Celsius. These are single-dose ampules, once taken out have to be administered within 30 mins," informed Head of global logistics at Dr. Reddy's lab.
The Sputnik V vaccine will be available in a few weeks after statutory clearances, informed Deepak Sapra, CEO of Dr Reddy's Laboratories after the Russian vaccines arrived in India on May 01. "Today, we have received 1,50,000 doses of Sputnik V vaccine here in Hyderabad. The vaccine will be available in a few weeks after it has gone through statutory clearances. The price will also be announced then," said CEO Sapra.
Sputnik V is the Russian made covid vaccine with an efficacy rate above 90%. 150,000 doses of Sputnik have arrived at Hyderabad in India on Saturday. The vaccines will be handed over to Dr Reddy's Laboratories, and soon to be distributed among the healthcare systems of the country.
#covid19 #covid vaccines #SputnikV #Russia #Indiacovidcrisis
With upsurge in country's COVID-19 cases, many organisations have come forward to offer their best during these tough times. Telangana's Calvary Temple has been converted into a COVID care centre. The 300-bed capacity centre was inaugurated by TRS leader and MLC K Kavitha. It is a highly equipped centre with oxygen support and has round the clock presence of doctors and nurses. The temple association is looking forward to further increase the bed capacity to 1,000 in coming days.
A Hyderabad-based start-up claims to have developed a portable and affordable oxygen generator. India is currently facing an acute shortage of medical oxygen amid a huge rise in Covid-19 cases. The Phi Factory co-founder Praveen Gorakavi said that the machine can support two patients for six hours, or one for twelve hours. It can prove to be crucial in saving lives while patients await medical care. Watch the full video for more.
Credit: HT Digital Content Duration: 02:45Published
As the country is reeling under the horrific second wave of pandemic and acute oxygen shortage, a start-up in Hyderabad came up with a invention to address the crisis. 'The Phi Factory' has created a portable oxygenerator, which works on Hydrogen Peroxide, under the name 'Project Vayuputra'. Vayuputra has been developed with an objective to support COVID-19 patients who are under home isolation. Price of this oxygenerator would be around Rs. 2,500 to Rs. 2,600 that includes the oxygenerator along with 10x2 liter bottles of Hydrogen Peroxide.
Sputnik Light is the single-shot version of Sputnik V. Its developers include Russia's health ministry, Gamaleya Research Center of Epidemiology and Microbiology, and the RDIF. On Thursday, they said..
While it must be understood that taking both doses of any vaccine whether it be Covishield, Covaxin or Sputnik, the ones that are available in India, are critical, here is what we know about one dose..
Microsoft’s Satya Nedalla is heartbroken with what India is going through right now. The COVID-19 second wave has hit the country and how. India is currently... BGR India Also reported by •IndiaTimes •Zee News